With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.
- Developing Exosome-Based RNA Therapeutics For CNS Regeneration
- CMC For Long-Acting Injectables For TB
- Drug Delivery Product Strategy: Aligning The Organization For Execution
- EU MDR: When Products Without An Intended Medical Purpose Meet Medicinal Substances
- The Companion Diagnostic Strategy That Combination Product Leaders Need
- Beyond The Inhaler: Expanding COPD Care With Nebulized Combination Therapy
- 7 Management Strategies For Combination Product Regulatory Success
- Avoiding Alcohol-Induced Dose Dumping In Oral Drug Formulation
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Exploring Lipid Nanoparticles For Drug Delivery
Using lipid nanoparticles (LNP) for drug delivery is a promising area of research. Discover the benefits of LNP delivery, the different types of lipid nanoparticles, their safety for drug delivery, and more.
-
Computational Modeling Of Injection-Related Tissue Responses
Optimizing delivery along with the formulation is the key to successful clinical outcomes. Research is necessary to understand the relationship between body morphology, injection force, and needle length.
-
Solubility With Lipid-Based Technologies For Oral & Injectable Formulations
Innovative approaches in developing formulations can help to improve a drug's safety and efficacy. Explore the decision for selecting the best-suited technology for formulating a complex molecule.
-
Is It Ever Too Soon To Start Your Performance Testing Assessment?
Developing a safe and effective injectable combination product involves performing risk assessments, establishing a set of Critical Quality Attributes (CQAs), and performing design verification testing.
-
PHI And Medical Devices: What Device Manufacturers Need To Know
Connected medical devices must treat Protected Health Information (PHI) protection as integral to patient safety and compliance. Understand the data flows and HIPAA requirements to design security.
-
Reformulation Of A Complex, High-Drug-Load, Modified Release Dosage Form
What if you could limit and position a formulation change as only a CMC prior approval supplement under the FDA’s scale-up and post-approval changes guidance?
-
Parenteral Packaging And Delivery Systems: Container Closure Integrity
Review the chapter, USP <1207> Package Integrity Evaluation – Sterile Products, which covers CCI and different methods of selection and validation.
-
A New Mindset For Combination Product Development
As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.
-
Designing Delivery Devices For Older Adults With Cognitive Impairment
Leverage our insights to improve your human factors studies and ensure the effective inclusion of older adults with mild cognitive impairment.
-
Transitioning From Vial To Prefilled Syringe
Understand how formulation development for a prefilled syringe affects manufacturing, driving the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Tom hosts multiple videocast series providing expert takes and insider perspectives on drug delivery:
FRANKLY FRAN
-
In this article, Fran DeGrazio recounts the evolution of drug delivery technologies as she underscores the need to innovate in the delivery of advanced therapies. Considering chronic diseases, rare diseases, and difficult-to-reach therapeutic targets, Fran offers suggestions for organizing and readying for the development and delivery of platforms, systems, and devices for next generation treatments, including personalized, precision medicines.

